A recent clinical study indicates that an anticholinergic medication used for overactive bladder may significantly alleviate hot flashes in men undergoing hormone therapy for prostate cancer.
A new clinical study published in the Journal of Clinical Oncology has highlighted the potential benefits of oxybutynin, a medication typically prescribed for overactive bladder, in managing hot flashes among men receiving hormone therapy for prostate cancer. Findings from the study, which included participants from the Mayo Clinic, reveal that oxybutynin was more effective than a placebo in reducing both the frequency and intensity of these hot flashes, a prevalent side effect that affects a significant number of men undergoing such treatments.
Hot flashes, reported to impact between 60% and 80% of men undergoing androgen deprivation therapy, can severely disrupt sleep, mood, and overall quality of life. Participants who were administered higher doses of the medication experienced notable improvements in their daily activities and overall well-being. Dr. Bradley Stish, the principal investigator, emphasized that symptoms like hot flashes often do not receive adequate attention despite their substantial impact on patients' lives.
The research involved 88 participants who were treated over six weeks, marking a crucial step towards understanding and addressing the lesser-discussed side effects of prostate cancer treatment. The study's outcomes could lead to improved management strategies and enhance the quality of life for many men dealing with these debilitating symptoms during their cancer treatment journey.
